Thailand Third-Generation IVF Hospitals: PGT Technology Eligibility Criteria & Hospital Selection Guide
Consultation Scenario: A 42-year-old woman, AMH 0.9 ng/mL, with a history of two miscarriages due to embryonic chromosomal abnormalities. Karyotype analysis of the couple showed no abnormalities. She asks: "Which hospital in Thailand has the highest success rate for third-generation IVF?" The dimensions that need to be unpacked behind this question include: the impact of age and ovarian reserve on oocyte yield, the type of PGT technology and laboratory testing capabilities, and the hospital's stability in embryo culture and cryopreservation. The following content is based on common clinical issues and professional observations.
I. Core Logic for Selecting a Third-Generation IVF Hospital in Thailand
The technical framework for third-generation IVF (PGT, Preimplantation Genetic Testing) in Thailand includes PGT-A (aneuploidy screening), PGT-SR (structural rearrangement detection), and PGT-M (monogenic disease detection). When choosing a hospital, the evaluation should not be "which is the best," but "which hospital's technical system matches the patient's own conditions."
- PGT Technology Platform: Currently, mainstream hospitals in Thailand use NGS (Next-Generation Sequencing) for PGT-A, while some centers also have aCGH and SNP array platforms. NGS offers advantages in resolution and throughput, but the sensitivity for detecting mosaicism varies among laboratories.
- Embryo Biopsy Stage: Most hospitals perform trophectoderm biopsy at the blastocyst stage (day 5-6), which has a lesser impact on embryo developmental potential compared to cleavage-stage biopsy.
- Laboratory Qualifications: Having a quality control system for the entire embryo freezing-thawing process, an independent genetics laboratory, or collaboration with a certified third-party laboratory are important hardware indicators.
When is it suitable to choose Thailand for PGT? It is mainly indicated for: couples where one or both partners are carriers of chromosomal structural abnormalities, known monogenic diseases, recurrent implantation failure (≥3 times), recurrent miscarriage (≥2 times) clearly related to embryonic chromosomal abnormalities, and advanced maternal age (≥38 years) wishing to reduce the risk of aneuploidy. When is it not suitable? When ovarian reserve is very low (AMH < 0.4 ng/mL), insufficient blastocysts can be obtained for biopsy, or there are uncontrolled uterine cavity pathologies, the clinical benefit of PGT will be significantly reduced.
II. Key Diagnostic Indicators and Individualized Assessment
Before starting the IVF process in Thailand, the required tests and their interpretation logic are as follows:
| Test Item | Clinical Significance | Impact on PGT Decision |
|---|---|---|
| AMH (Anti-Müllerian Hormone) | Reflects ovarian reserve | When AMH < 1.0 ng/mL, the number of oocytes retrieved may be limited; assessment is needed to determine if enough blastocysts can be formed for biopsy. |
| FSH (Follicle-Stimulating Hormone) | Baseline endocrine level; FSH > 10 IU/L suggests possible diminished ovarian response | High FSH with low AMH may require adjustment of the stimulation protocol, and the PGT cycle cancellation rate may increase. |
| Antral Follicle Count (AFC) | Total number of antral follicles in both ovaries, directly related to oocyte yield | When AFC < 5, the risk of embryo loss needs thorough communication. |
| Chromosome Karyotype Analysis | To rule out chromosomal structural abnormalities in the couple (e.g., balanced translocation, Robertsonian translocation) | Abnormal karyotype is a clear indication for PGT-SR; a laboratory with corresponding detection capabilities must be chosen. |
| Carrier Screening for Genetic Diseases | To screen for common recessive genetic diseases (e.g., thalassemia, spinal muscular atrophy) | When both partners are carriers, PGT-M is required, demanding higher gene detection capabilities from the laboratory. |
| Hysteroscopy | To evaluate the uterine cavity, rule out polyps, adhesions, endometritis, etc. | Uterine cavity abnormalities can affect implantation success rates; treatment should be completed before embryo testing. |
Professional Observation: A common clinical issue is that some patients believe PGT can completely replace prenatal diagnosis. In reality, the number of cells biopsied from an embryo is limited (usually 5-10 trophectoderm cells), and the test results carry a risk of approximately 2%-5% false negatives and false positives, and cannot detect all genetic abnormalities. Therefore, prenatal confirmation via amniocentesis is still necessary after transfer.
III. Differences in Undergoing PGT in Thailand for Women of Different Ages
Under 35 years: If there is no clear genetic indication, the benefit of PGT-A is relatively limited. The aneuploidy rate in embryos for this age group is about 20%-30%, and high live birth rates can already be achieved through morphological selection. Unless there is a history of recurrent miscarriage or implantation failure, routine PGT is not recommended. The suitable population is mainly carriers of monogenic diseases or chromosomal structural abnormalities.
35-40 years: The embryonic aneuploidy rate rises to 40%-50%. PGT-A can effectively screen for chromosomal numerical abnormalities and reduce miscarriage rates. For this age group, the impact of ovarian reserve on oocyte yield needs special attention. When AMH > 1.2 ng/mL, sufficient blastocysts for biopsy can usually be obtained. Some hospitals in Thailand may recommend combining with time-lapse embryo imaging for assisted selection for this age group.
Over 40 years: The embryonic aneuploidy rate can reach 70%-80%. PGT-A offers the highest clinical value, but it also faces risks of low oocyte yield, low blastocyst formation rate, and insufficient number of embryos available for biopsy. When AMH < 0.5 ng/mL, it is necessary to assess suitability for entering a PGT cycle; some patients may be advised to consider oocyte cryopreservation or an egg donation program first. Thai hospitals typically require recent AMH and AFC data (within the last 3 months) for such cases to develop an individualized stimulation strategy.
IV. Technical Characteristics and Differences Among Major Hospitals in Thailand
There are about a dozen centers in Thailand offering third-generation IVF services, with differences in technical routes and areas of expertise. The following is an objective overview from a technical perspective and is not intended as a ranking:
| Hospital/Center | PGT Technology Platform | Laboratory Features | Common Indication Focus |
|---|---|---|---|
| Jetanin | NGS + aCGH | In-house genetics laboratory, high stability in embryo culture system | PGT-A, advanced maternal age, recurrent implantation failure |
| Piyawate | NGS | Collaboration with certified third-party laboratory, emphasis on dynamic embryo assessment | PGT-A, PGT-SR, chromosomal balanced translocation |
| Bumrungrad | NGS + SNP | Mature international patient service process, robust multidisciplinary collaboration | PGT-M, monogenic diseases, complex genetic disorders |
| Siam | NGS | Strict laboratory quality control standards, extensive experience in embryo biopsy | PGT-A, recurrent miscarriage, advanced maternal age |
| Phyathai | aCGH + NGS | Highly standardized embryo culture and biopsy procedures | PGT-A, PGT-SR, recurrent implantation failure |
It is important to note that hospitals differ in embryo biopsy techniques (laser-assisted vs. mechanical), freezing methods (vitrification), and genetic counseling support services. When choosing, it is advisable to verify whether the laboratory holds relevant certifications (e.g., ISO 15189 or CAP accreditation) and confirm that genetic reports are issued by qualified clinical geneticists.
V. Actual Process and Timeline
The complete process for third-generation IVF in Thailand is typically divided into the following stages:
- Stage 1 (Preparation in Home Country, 1-2 months): Complete basic tests for both partners (AMH, FSH, LH, thyroid function, chromosome karyotype, infectious disease screening, semen analysis, etc.), genetic counseling, and determine the type of PGT. Simultaneously, arrange passports (valid for at least 6 months) and visas (medical visa or tourist visa, depending on hospital requirements).
- Stage 2 (Travel to Thailand for Ovarian Stimulation, 12-15 days): Arrive in Thailand on day 2-3 of menstruation for baseline ultrasound and hormone testing. Start ovarian stimulation (8-12 days) with monitoring of follicular development and hormone levels. Oocyte retrieval occurs 36 hours after the trigger.
- Stage 3 (Embryo Culture and Biopsy, 5-7 days): After oocyte retrieval, perform IVF. Culture embryos to the blastocyst stage (day 5-6). Perform trophectoderm biopsy on blastocysts, followed by embryo cryopreservation.
- Stage 4 (Genetic Testing, 2-4 weeks): Biopsied cells are sent to the genetics laboratory for NGS or aCGH analysis. A report on chromosomal copy number variations or gene mutations is issued.
- Stage 5 (Frozen Embryo Transfer, 1-2 months): Based on test results, select a chromosomally normal blastocyst. In a subsequent cycle, prepare the endometrium and perform frozen embryo transfer (FET). Pregnancy test is done 12-14 days after transfer.
Overall, from the initial consultation to the completion of transfer, it usually takes 3-4 months. If the patient has completed all tests in their home country, the time can be shortened to 2.5-3 months. It is important to note that during the PGT testing cycle, some embryos may be non-transferable due to chromosomal abnormalities, requiring mental and financial preparation in advance.
Timeline Planning Reminder: Thai hospitals usually require patients to arrive 1-2 weeks before starting ovarian stimulation. It is advisable to avoid Thai public holidays (e.g., Songkran in April, King's Birthday in December) to prevent affecting laboratory scheduling. Some hospitals allow patients to return home while waiting for embryo test results, but the timeliness of international logistics and report delivery must be confirmed.
VI. Most Commonly Overlooked Details and Potential Risks
During the third-generation IVF process in Thailand, the following details are often overlooked but have a substantial impact on outcomes:
- Number and Quality of Cells Biopsied: Typically, 5-8 trophectoderm cells are taken; some laboratories may take up to 10 or more. Too few cells can lead to test failure or inaccurate results, but excessive biopsy may also affect the embryo's subsequent developmental potential and survival rate.
- Management of Mosaicism: About 2%-5% of embryos exhibit mosaicism (coexistence of normal and abnormal cell lines). Different laboratories have different thresholds for determining the mosaic ratio (usually 20%-40% for low-level mosaicism, >40% for high-level). Some hospitals classify mosaic embryos as "transferable" but require additional counseling; this should be clarified in advance.
- Detection Range for Microdeletions/Microduplications: PGT-A primarily detects chromosomal numerical abnormalities and large structural abnormalities (>10 Mb). It may not identify small deletions or duplications (<1 Mb). If there is a known microdeletion/microduplication in the family, it is necessary to confirm whether the laboratory's testing protocol covers that region.
- Risk of Blastocyst Culture Failure: In Thailand, about 10%-20% of fertilized eggs fail to develop to the blastocyst stage. This percentage can be higher for patients with low ovarian reserve or poor sperm quality. This means there may not be enough embryos for biopsy.
- Legal and Embryo Disposal: Thailand has specific regulations regarding the disposal of surplus embryos (including those with chromosomal abnormalities), requiring signed informed consent. Some hospitals do not allow embryos to be taken out of the country; all embryos must be processed within Thailand.
VII. Physician's Perspective: Applicability Boundaries and Decision Logic of PGT Technology
From a reproductive physician's clinical decision-making perspective, PGT is not a "more is better" technology. When advising patients on PGT, physicians typically evaluate the following three core issues:
First, can the patient truly benefit from PGT? For recurrent miscarriage caused by chromosomal aneuploidy, PGT-A can reduce the miscarriage rate but cannot completely eliminate the risk (due to a 2%-5% test error and other variables in post-transfer embryo development). For monogenic diseases, the accuracy of PGT-M depends on the type of gene mutation and the specificity of the detection method; linkage analysis or direct mutation testing within the family is required first.
Second, does the patient's ovarian reserve support a PGT cycle? A PGT cycle requires embryos to develop to the blastocyst stage for biopsy, which necessitates a certain number of good-quality oocytes. Clinical consensus suggests that at least 6-8 mature oocytes are needed to have a reasonable chance of forming 2-3 blastocysts suitable for biopsy. When AMH < 0.8 ng/mL or AFC < 4, physicians may recommend against PGT or consider egg donation.
Third, can the laboratory's testing capabilities match the patient's specific problem? Different hospitals' genetic testing platforms vary in resolution, detection range, and reporting time. For example, for carriers of balanced chromosomal translocations, a laboratory with SNP array or specific breakpoint detection capabilities must be chosen; otherwise, it may not be possible to accurately distinguish between normal and translocation carrier embryos.
How to determine if a Thai hospital is suitable for you? It is recommended to ask the hospital to provide the following information: PGT cycle data from the past year (biopsy rate, blastocyst utilization rate, clinical pregnancy rate), certification documents for the genetics laboratory, and a description of the testing protocol for your specific genetic issue. If the hospital cannot provide this data, caution is warranted.
VIII. Special Case Management: Balanced Chromosomal Translocations and Monogenic Diseases
Carriers of Balanced Chromosomal Translocations: When performing PGT-SR for such patients, it is necessary to detect whether the embryo has an unbalanced rearrangement related to the translocation. Some hospitals in Thailand use NGS combined with parental karyotype analysis for this purpose, but approximately 10%-15% of embryos cannot be clearly distinguished as normal or carrier. It is advisable to choose a hospital with genetic specialists on staff and undergo detailed genetic counseling before transfer.
Monogenic Diseases: PGT-M requires prior confirmation of the pathogenic mutation site in both partners and establishment of haplotype analysis. Thai hospitals usually require genetic test reports from a top-tier hospital in the patient's home country and need 3-4 weeks for probe design and preliminary experiments. If the mutation site is unclear or is a de novo mutation, the feasibility of PGT-M may be limited.
Mitochondrial Diseases: Currently, most hospitals in Thailand do not have the capability for PGT testing for mitochondrial genetic diseases. For diseases related to mitochondrial DNA mutations, referral to a center with specific experience (e.g., Bumrungrad or programs collaborating with overseas laboratories) is necessary, and the testing scope and technical route must be confirmed in advance.
Risk Reminder: No PGT technology can guarantee 100% genetic normality of an embryo. The test results only pertain to the cells sent for analysis and do not fully represent the genetic status of the entire embryo. Prenatal diagnosis (amniocentesis or chorionic villus sampling) is still required after transfer to ultimately confirm the fetal chromosomal and genetic condition.
Checklist Reminder: Within 3 months before traveling to Thailand, it is recommended to complete AMH, chromosome karyotype, carrier screening for genetic diseases, and comprehensive infectious disease testing for both partners. Some tests (e.g., chromosome karyotype) are valid long-term, while AMH, semen analysis, etc., should be updated within 6 months. Coordinate the test list with the hospital in advance to avoid cycle delays due to incomplete documentation.
